Prognostic impact of the Hevylite Assay in patients with IgG or IgA multiple myeloma treated within the GMMG-MM5 trial

This study assessed Hevylite Assay (HLCr) normalization in 360 multiple myeloma patients from the prospective GMMG-MM5 trial. The assay quantifies IgG and IgA kappa/lambda fractions to determine treatment response. HLCr normalization steadily increased during therapy. Achieving normalization showed a trend toward prolonged progression-free survival (PFS) but not overall survival (OS). However, the analysis did not support the general use of HLCr normalization as a predictive response parameter for PFS or OS.